No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Drug Manufacturers - Specialty & Generic
NATCO Pharma Limited, an Indian pharmaceutical company established in 1981 and headquartered in Hyderabad, specializes in the development, manufacturing, and commercialization of both finished dosage formulations (FDFs) and active pharmaceutical ingredients (APIs). The company's finished pharmaceutical products address a wide array of therapeutic areas, with a significant focus on various oncological conditions, including cancers affecting the blood, liver, kidneys, lungs, brain, breasts, and ovaries. Its active pharmaceutical ingredients are employed in critical therapeutic categories such as oncology, central nervous system disorders, pain management, and cardiovascular care. NATCO also offers specialized treatments, including orthopedic products like oral and injectable bisphosphonates, and innovative gastroenterology solutions for chronic hepatitis-B and hepatitis-C. Furthermore, their portfolio encompasses cardiology and diabetology products designed to manage conditions such as hypertension, stable angina, and congestive heart failure (CHF). Beyond its pharmaceutical offerings, the company provides contract manufacturing services. Notably, NATCO Pharma has also diversified into agrochemicals, delivering biological pest management solutions to control insects, diseases, and weeds across various crops. With a significant international footprint, NATCO Pharma markets its diverse product range in approximately 50 countries globally.
www.natcopharma.co.inNo one on the platform currently holds NATCOPHARM.BO.
No tracked institution reports a position in NATCOPHARM.BO as of their last filing.
No one on the platform has traded NATCOPHARM.BO yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 13.5% | 25.9% | 25.9% | — | — | — |
| Rev. Growth % | -8.0% | 14.7% | ||||
| Profit Margin % | 34.8% | 29.4% | 27.9% | |||
| Free Cash Flow Margin % | 33.8% | 20.3% | 12.2% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2027 | $32.4B | -20.5% | $43.24 | $29.92–$51.23 | — | 9 |
| 2028 | $36.5B | +12.8% | $50.40 | $33.30–$57.46 | — | 9 |
| 2029 | $43.3B | +18.7% | $61.75 | $56.05–$64.60 | — | 3 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 5 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-14 | $8.04 | $11.50 | +43.0% |
| 2026-05-29 | $15.76 | $11.75 | -25.4% |
| 2026-02-12 | $5.27 | $8.43 | +60.0% |
| 2025-11-14 | $24.56 | $28.94 | +17.8% |
| 2025-08-12 | $36.90 | $26.84 | -27.3% |
| 2025-05-28 | $10.80 | $23.00 | +113.0% |
| 2025-02-12 | $19.40 | $7.40 | -61.9% |
| 2024-11-12 | $32.95 | $37.80 | +14.7% |
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| NATCOPHARM.BONATCO Pharma Limited | $819.00 | +0.48% | $146.6B | — |
| APLLTD.BOAlembic Pharmaceuticals Limited | $822.40 | +1.47% | $161.6B | — |
| APLLTD.NSAlembic Pharmaceuticals Limited | $824.75 | +1.70% | $162.1B | — |
| CAPLIPOINT.NSCaplin Point Laboratories Limited | $2570.60 | -6.69% | $195.4B | — |
| CONCORDBIO.BOConcord Biotech Limited |
| $1471.50 |
| -2.33% |
| $154.2B |
| — |
| CONCORDBIO.NSConcord Biotech Limited | $1473.00 | -2.17% | $154.1B | — |
| GRANULES.BOGranules India Limited | $872.50 | -4.08% | $217.2B | — |
Source: Financial Modeling Prep · peers by sector/industry